Study Suggests Virtual Buprenorphine Aids Treatment Retention

A new claims-based study is offering one of the clearest looks yet at how virtual-only buprenorphine care compares to treatment from traditional, in-person clinicians, and the results lean in favor of telehealth on one of the measures that matters most: whether patients stay in treatment months later.

Why Medical Detox and Ongoing Treatment Matter

Buprenorphine is one of the FDA-approved medications used to manage opioid use disorder, and it works best as part of a supervised, ongoing treatment relationship rather than a one-time prescription.

Since the COVID-19 pandemic prompted federal waivers allowing buprenorphine to be prescribed without an in-person exam, telehealth-based opioid treatment has grown substantially, making studies like this one increasingly relevant to whether those flexibilities should stay in place.

What the New Study Found

Researchers examined more than 17,500 buprenorphine treatment starts among adults with commercial or Medicare Advantage coverage between September 2019 and December 2023, comparing patients who began treatment with a virtual-only clinician against those treated in person.

Virtual-only inductions made up a small share of the total, about 3 percent. Patients in virtual-only care attended more follow-up visits in the six months after starting treatment, 8.5 visits on average versus 5.7 for in-person patients, and were more likely to still be on buprenorphine at six months, 59.0 percent versus 52.9 percent.

That treatment retention gap is where the study’s headline finding lands: more contact with a clinician and higher odds of remaining in addiction treatment at six months.

The one place virtual-only care looked weaker was total continuous days on buprenorphine without a gap, which came in lower than the in-person group, a pattern researchers suggest may reflect more frequent brief interruptions or restarts even among patients who ultimately stayed engaged. Notably, the two groups looked similar demographically.

Patients in virtual-only and in-person care were about equally likely to live in urban areas, meaning telehealth was not simply filling a gap in places without local providers.

Understanding Buprenorphine as Medication for Opioid Use Disorder

Buprenorphine is a partial opioid agonist, meaning it activates opioid receptors enough to prevent withdrawal and cravings without producing the same intensity of effects as full opioid agonists like heroin or fentanyl.

It is typically combined with counseling and regular clinical check-ins, which is why visit frequency and six-month treatment retention are both meaningful measures of how well a treatment model is working.

Levels of Detox and Ongoing Care Explained

Buprenorphine treatment can begin in a medically supervised outpatient setting, a residential program, or, as this study shows, through telehealth. The appropriate setting still depends on the severity of withdrawal risk and any co-occurring medical or psychiatric conditions.

People with more complex needs, including a history of relapse or unstable housing, are generally better served by more structured, in-person levels of care rather than a virtual-only start, even as this data suggests telehealth can support strong treatment retention for many patients.

Finding Medical Detox and Buprenorphine Treatment

Anyone considering buprenorphine treatment, whether through telehealth or an in-person clinician, should never attempt opioid withdrawal without medical supervision.

Detox.com’s directory can help identify detox centers that offer buprenorphine programs, including those offering telehealth options alongside in-person care. Call 800-996-6135(Sponsored) to find a program suited to your situation.